These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25502481)

  • 21. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
    Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
    J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.
    Ioannou GN; Splan MF; Weiss NS; McDonald GB; Beretta L; Lee SP
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):938-45, 945.e1-4. PubMed ID: 17509946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B.
    Lin CL; Liu CH; Wang CC; Liang CC; Su TH; Liu CJ; Kao JH
    J Clin Gastroenterol; 2015 Sep; 49(8):705-13. PubMed ID: 25319739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer.
    Park YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Han S; Jeon MY; Heo JY; Song K; Kim SU
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1221-1229. PubMed ID: 27859587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study.
    Liu J; Zhao J; Zhang Y; Ji Y; Lin S; Dun G; Guo S
    J Ultrasound Med; 2017 Feb; 36(2):285-293. PubMed ID: 28039877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.
    Kim MN; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Song KJ; Park YN; Han KH
    Hepatology; 2015 Jun; 61(6):1851-9. PubMed ID: 25643638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
    Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
    J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis.
    Tanaka K; Sakai H; Hashizume M; Hirohata T
    Jpn J Cancer Res; 1998 Dec; 89(12):1241-50. PubMed ID: 10081484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.
    Mendeni M; Focà E; Gotti D; Ladisa N; Angarano G; Albini L; Castelnuovo F; Carosi G; Quiros-Roldan E; Torti C
    Clin Infect Dis; 2011 May; 52(9):1164-73. PubMed ID: 21467023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients.
    Abdelgawad IA
    J Clin Pathol; 2015 Feb; 68(2):154-60. PubMed ID: 25430496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
    Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
    J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
    Kim MN; Lee JH; Chon YE; Ha Y; Hwang SG
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):433-439. PubMed ID: 31490417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
    Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
    Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
    Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
    Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.